Neuroventi participates in ‘BIO KOREA 2023’ partnering

23-04-28

Neuroventi, which specializes in the development of treatments for intractable brain development disorders, received the world's first orphan drug designation (ODD) for 'NV01-A02', a candidate for autism treatment, from the U.S. Food and Drug Administration (FDA) on October 24, 2022. ), we plan to hold partnering meetings with domestic and foreign pharmaceutical bio companies by attending Bio Korea 2023, which will be held at COEX from May 10 (Wednesday).

Foreign companies' interest in Neuroventi's integrated treatment platform for brain development disorders and central nervous system CDRO service has already been confirmed through the Bio Europe partnering event last year.

Autism spectrum disorder is characterized by various accompanying symptoms such as lack of sociability, repetitive stereotyped behaviors, epilepsy, anxiety, and depression. It is very important to develop a treatment that does not cause concerns, said a Neuroventi official.

In addition, with respect to discovering treatments for central nervous system diseases, which is gaining increasing interest in Korea, based on various brain and neuroscience research experiences that Neuroventi boasts as its strength, discovering and testing therapeutic candidates for central nervous system (nervous, mental, and neurodevelopmental) disorders. Non-clinical CDRO services, such as clinical research consulting and research services for non-clinical efficacy evaluation and safety evaluation of candidate substances, can also be provided.

At this Bio Korea 2023 event, we expect good partnership results as numerous bio-health professional researchers and bio venture companies participate, and we hope that the CDRO service provided by Neuroventi will become a catalyst for the development of treatments for central nervous system diseases.